The company

The pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications.


1995   Dr. Smit and his co-workers made a coincidental finding of increased autofluorescence of the skin in many diabetes patients when they were performing fluorescein capillary leakage studies in diabetes.
1996   Dr. Smit and Dr. Graaff developed dedicated prototypes to assess skin autofluorescence in human
1998   The first clinical studies in diabetes and renal failure were started with an advanced prototype of the AGE Reader in the University Hospital Groningen, the Netherlands
1999   Filed patent application for the AGE Reader and published the first scientific report on the clinical use of AGE Reader prototype in diabetic patients
2000   Initiated the first large scale follow-up study in the Zwolle region
2003   Dr. Smit and Dr. Graaff founded DiagnOptics in Groningen, the Netherlands
2004   The first clinical study on AGE Reader were published in Diabetologia
2005   AGE Reader was first shown to future users (EASD, Athens 2005)
2006   AGE Reader received CE approval for commercialization in Europe
2009   AGE Reader CU (Compact Unit) received CE approval
2010   DiagnOptics received ISO 13485 certification for its Quality Management System
2011   Diab-spot was first shown to future users (Prediabetes, Madrid 2011)
2011   Diab-spot received CE approval
2012   First demonstration of the AGE Reader mu at the EASD 2012 in Berlin
2013   AGE Reader mu received CE approval
2014   Installed base > 2000 units
2015   Ranked 33rd in Deloitte Technology Fast50 and sector winner Life Sciences
More Information
Request informations

Would you like to learn more about our products? Request any information you wish to receive here.


Our contact details


Follow us on LinkedIn

About the company

Find information about Diagnoptics.

Information for patients

Find information about Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.a